



Cipla Ltd.

Registered Office :
Cipla House
Peninsula Business Park
Ganpatrao Kadam Marg
Lower Parel
Mumbai – 400 013
India

17th December 2014

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

Dear Sirs,

This has reference to your email dated 17th December 2014 regarding news item appearing in The Times of India titled "Novartis drags Cipla to court".

We wish to clarify that as part of Company's mission to provide affordable access, Company continues to launch various products in various markets including India to serve the needs of patients. The Company has accordingly launched product Unibrez recently. Novartis India Limited has approached Delhi High Court to restrain the Company from marketing this product. The matter is sub-judice.

The above development is in the ordinary course of business. The Company has over 1500 products in its portfolio which generate annual revenue of over Rs.10,000 crores and hence the revenues/profits from the product is not expected to be material in the current financial year.

Thank you,

Yours faithfully,
For Cipla Limited

Rajesh Garg
Executive Director and Global Chief Financial Officer